A Prospective, multicentre, Phase II Seamlessly Followed by Phase III Clinical Study to Evaluate the Immunogenicity and Safety of Biological E's CORBEVAX Vaccine for Protection Against COVID-19 Disease When Administered to COVID-19-Negative Adult Subjects
Latest Information Update: 09 Nov 2022
At a glance
- Drugs COVID-2019 vaccine-Biological E. Limited (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 31 Oct 2022 Results published in the Vaccine